On October 9, in response to the overseas clinical failure of the core product vometinib, Alice stated that the FURVENT study data needed to be thoroughly analyzed to determine follow-up development and regulatory communication plans. The company believes that the results of this FURVENT study will not affect the third quarter and future sales of vometinib. The current sales of this drug mainly come from first-line treatment indications for EGFR sensitive mutations. Ellis said that at the FURVENT Research Global Research Conference held later, experts believed that vormetinib had met previous expectations for the EGFR 20 exon insertion mutation. There was a big difference between the progression-free survival period of the chemotherapy team and the researchers' evaluation results by the blind independent center. Apart from this difference, all other data on vometinib performed well.

On October 9, in response to the overseas clinical failure of the core product vometinib, Alice stated that the FURVENT study data needed to be thoroughly analyzed to determine follow-up development and regulatory communication plans. The company believes that the results of this FURVENT study will not affect the third quarter and future sales of vometinib. The current sales of this drug mainly come from first-line treatment indications for EGFR sensitive mutations. Ellis said that at the FURVENT Research Global Research Conference held later, experts believed that vormetinib had met previous expectations for the EGFR 20 exon insertion mutation. There was a big difference between the progression-free survival period of the chemotherapy team and the researchers' evaluation results by the blind independent center. Apart from this difference, all other data on vometinib performed well.